High-risk neuroblastoma stem cell treatment after initial response
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests intensive treatment (high-dose “consolidation”) followed by rescue with your own stem cells for high-risk neuroblastoma. It may help patients keep the cancer from coming back after it has improved or stabilized from initial chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were younger than 30 when you were diagnosed with neuroblastoma.
- After initial chemotherapy, your scans/bone marrow (disease evaluation) showed complete or partial response, or stable disease.
- Your blood counts have recovered enough after the last chemotherapy phase to safely proceed to the next treatment.
- You do not have an infection that is not under control right now.
- You must be able to provide enough frozen stem cells from before the consolidation starts (with backup cells strongly encouraged).
- Your heart, lungs, liver, and kidneys must meet minimum function checks, and you must have recovered from the side effects of the last chemotherapy cycle.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies an allogeneic (donor) stem cell transplant for children with stage 4 neuroblastoma. It looks at whether the transplant can improve outcomes after chemotherapy and radiotherapy when tumor markers and tiny blood/bone marrow disease are gone.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This Phase 3 trial tests treatments for children and teens with high-risk neuroblastoma, aiming to improve outcomes by using biology-based risk information. It also requires limited prior chemotherapy and specific timing after diagnosis.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This trial tests a vaccine, combined with two other immune-boosting drugs (β-glucan and GM-CSF), to see if it can help keep neuroblastoma from coming back. It's for people who have already completed standard treatment and are in remission.
This trial tests whether combining your child's own immune cells (NK cells) with a targeted antibody (GD2) can help treat high-risk neuroblastoma. It is for children who are in the maintenance phase, or whose cancer has returned or not responded to standard treatment.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.